Annotation Detail for RAB27A

Basic Information
Top
Pathway ID | Pathway Name |
---|
| Diabetes pathways |
Desease ID | Desease Name |
---|
| Immune system diseases |
| Primary immunodeficiency |
H00101 | Other phagocyte defects |
Desease ID | Desease Name |
---|
1944 | Breast cancer |
Desease Name |
---|
Griscelli syndrome, type 2 |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
C103303 |
alitretinoin |
alitretinoin results in decreased expression of RAB27A mRNA | decreases expression | 16449964
|
C103303 |
alitretinoin |
RAB27A gene mutant form results in decreased susceptibility to alitretinoin | decreases response to substance | 16449964
|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of RAB27A mRNA | affects expression | 16483693
|
D020122 |
tert-Butylhydroperoxide |
tert-Butylhydroperoxide results in increased expression of RAB27A mRNA | increases expression | 15336504
|
D016572 |
Cyclosporine |
Cyclosporine results in increased expression of RAB27A mRNA | increases expression | 20106945
|
C004648 |
testosterone enanthate |
testosterone enanthate affects the expression of RAB27A mRNA | affects expression | 17440010
|
C025643 |
vinclozolin |
vinclozolin affects the expression of RAB27A mRNA | affects expression | 19015723
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
4.02 | 18287403 |
MESH:D001008 |
Anxiety Disorders |
|
vinclozolin |
3.89 | 19015723 |
MESH:D001943 |
Breast Neoplasms |
|
alitretinoin |
3.08 | 16344269 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
2.73 | 12371664 |
MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.14 | 19486331 |
MESH:D003456 |
Cryptorchidism |
|
vinclozolin |
4.72 | 14966744 |
MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
3.18 | 19224547 |
MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.56 | 12639820 12168785 |
MESH:D030342 |
Genetic Diseases, Inborn |
|
vinclozolin |
5.40 | 16973722 |
MESH:D005832 |
Genital Diseases, Male |
|
vinclozolin |
5.82 | 16417039 |
MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.68 | 8708960 |
OMIM:607624 |
GRISCELLI SYNDROME, TYPE 2 |
marker/mechanism |
|
| |
MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
4.88 | 15720958 |
MESH:D019247 |
HIV Wasting Syndrome |
|
testosterone enanthate |
6.27 | 17440010 |
MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.19 | 10903974 |
MESH:D007248 |
Infertility, Male |
|
vinclozolin |
3.24 | 16467254 |
MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
4.96 | 15604871 |
MESH:D017492 |
Keratosis, Seborrheic |
|
alitretinoin |
6.10 | 16144296 |
MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.50 | 18776723 10903974 8314463 |
MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.00 | 12371664 |
MESH:D007984 |
Leydig Cell Tumor |
|
vinclozolin |
5.19 | 16417039 |
MESH:D008175 |
Lung Neoplasms |
|
alitretinoin |
2.65 | 16413115 |
MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.31 | 16801185 |
MESH:D009369 |
Neoplasms |
|
alitretinoin |
3.38 | 16946489 |
MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
4.96 | 17954296 |
MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.57 | 19348381 18481113 |
MESH:D017499 |
Porokeratosis |
|
alitretinoin |
6.52 | 16144296 |
MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.51 | 12371664 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
vinclozolin |
4.36 | 18220299 18042343 19015723 |
MESH:D011469 |
Prostatic Diseases |
|
vinclozolin |
5.40 | 18220299 |
MESH:D011472 |
Prostatitis |
|
vinclozolin |
5.40 | 18629315 |
MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.31 | 16882103 |
MESH:D012878 |
Skin Neoplasms |
|
tert-Butylhydroperoxide |
2.81 | 8532709 |
MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.50 | 1336536 |
MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
4.96 | 17120751 |